Recently Featured

Decoding Resistance to Targeted Therapy via New Cancer Models

April 26, 2026
ATCC and the Broad Institute have developed engineered isogenic cancer models to replicate resistance to targeted therapies, focusing initially on osimertinib, a next-generation epidermal growth factor receptor (EGFR) inhibitor for non-small cell lung cancer (NSCLC) with EGFR mutations. This advancement addresses a significant challenge in oncology: the treatment resistance that often develops over time. While…

Podcast Examines Clinical Trial Supply Chain with Almac Clinical Services

April 26, 2026
A recent podcast delves into the intricate journey of clinical trial supplies, detailing how investigational medicines transition from initial planning stages to global distribution. Almac Clinical Services, a leader in this field, highlights the critical processes involved in ensuring that these supplies reach patients safely and punctually. This exploration is particularly relevant as the demand…

Nektar’s long-term mid-stage alopecia data fuels Phase 3 plans

April 26, 2026
Nektar Therapeutics has reported data from the extension phase of its Phase 2b trial for alopecia areata, which has largely met the expectations of Wall Street analysts. This outcome is pivotal for Nektar as it seeks to advance its investigational therapy, rezpegaldesleukin, into Phase 3 trials. The data, while derived from a trial that did…

Nektar Therapeutics’ Rezpeg Shows Promising Results in Alopecia Treatment

April 26, 2026
Nektar Therapeutics announced on Monday that extended use of its experimental drug, rezpeg, has demonstrated significant efficacy in promoting hair growth among individuals suffering from severe alopecia areata, an autoimmune disorder that targets hair follicles. In a year-long study, 27% of participants receiving either a low or high dose of rezpeg achieved a clinically meaningful…

Ongoing Cases